Your browser doesn't support javascript.
loading
Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.
Gerber, Simon; Gaida, Annette; Spiegl, Nicole; Wymann, Sandra; Antunes, Adriano Marques; Menyawi, Ibrahim El; Zurbriggen, Brigitte; Hubsch, Alphonse; Imboden, Martin.
Afiliação
  • Gerber S; Department of Research and Development, CSL Behring AG, Wankdorfstrasse 10, 3000, Bern 22, Switzerland. simon.gerber@cslbehring.com.
  • Gaida A; Department of Research and Development, CSL Behring AG, Wankdorfstrasse 10, 3000, Bern 22, Switzerland.
  • Spiegl N; Department of Quality Control, CSL Behring AG, Bern, Switzerland.
  • Wymann S; Department of Research and Development, CSL Behring AG, Wankdorfstrasse 10, 3000, Bern 22, Switzerland.
  • Antunes AM; Department of Quality Control, CSL Behring AG, Bern, Switzerland.
  • Menyawi IE; Department of Research and Development, CSL Behring AG, Wankdorfstrasse 10, 3000, Bern 22, Switzerland.
  • Zurbriggen B; Department of Project Management, CSL Behring AG, Bern, Switzerland.
  • Hubsch A; Department of Medical Affairs, CSL Behring AG, Bern, Switzerland.
  • Imboden M; Department of Research and Development, CSL Behring AG, Wankdorfstrasse 10, 3000, Bern 22, Switzerland.
BioDrugs ; 30(5): 441-451, 2016 Oct.
Article em En | MEDLINE | ID: mdl-27646589
ABSTRACT

BACKGROUND:

Hemolysis, a rare but potentially serious complication of intravenous immunoglobulin (IVIG) therapy, is associated with the presence of antibodies to blood groups A and B (isoagglutinins) in the IVIG product. An immunoaffinity chromatography (IAC) step in the production process could decrease isoagglutinin levels in IVIG.

OBJECTIVES:

Our objectives were to compare isoagglutinin levels in a large number of IVIG (Privigen®) batches produced with or without IAC and to assess the feasibility of the production process with an IAC step on an industrial scale.

METHODS:

The IAC column comprised a blend of anti-A and anti-B resins formed by coupling synthetic blood group antigens (A/B-trisaccharides) to a base bead matrix, and was introduced towards the end of the industrial-scale IVIG manufacturing process. Isoagglutinin levels in IVIG were determined by anti-A and anti-B hemagglutinin direct and indirect methods according to the European Pharmacopoeia (Ph. Eur.) and an isoagglutinin flow cytometry assay. IVIG product quality was assessed with respect to the retention of immunoglobulin G (IgG) subclasses, specific antibodies, and removal of IgM using standardized procedures.

RESULTS:

The IAC step reduced isoagglutinins in IVIG by two to three titer steps compared with lots produced without IAC. The median anti-A and anti-B titers with IAC were 18 and 14, respectively, when measured by the Ph. Eur. direct method, and 12 and <1, respectively, when measured by the Ph. Eur. indirect method. The isoagglutinin flow cytometry assay showed an 87-90 % reduction in isoagglutinins in post-IAC versus pre-IAC fractions. IAC alone reduced anti-A and anti-B of the IgMs isotype by 92.5-97.8 % and 95.4-99.2 %, respectively. Other product quality characteristics were similar with and without IAC.

CONCLUSIONS:

IAC is an effective method for reducing isoagglutinin levels in IVIG, and it is feasible on an industrial scale.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cromatografia de Afinidade / Imunoglobulinas Intravenosas / Hemaglutininas Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cromatografia de Afinidade / Imunoglobulinas Intravenosas / Hemaglutininas Idioma: En Ano de publicação: 2016 Tipo de documento: Article